Literature DB >> 11896489

The effects of topiramate and sex hormones on energy balance of male and female rats.

D Richard1, F Picard, C Lemieux, J Lalonde, P Samson, Y Deshaies.   

Abstract

OBJECTIVE: The effects of topiramate (TPM) on components of energy balance were tested in male and female rats that were (i) left intact, (ii) castrated or (iii) castrated with replacement therapies consisting of testosterone administration in orchidectomized (OCX) rats and of estradiol or progesterone treatments in ovariectomized (OVX) rats.
METHODS: TPM was mixed into the diet and administered at a dose of 60 mg per kg of body weight. Male and female rats were treated for 28 and 35 days, respectively. At the end of the treatment period, variables of energy balance and determinants of lipid and glucose metabolism were assessed.
RESULTS: TPM reduced energy and fat gains in both male and female rats either in the absence or in the presence of hormone replacement therapies. In male rats, it also decreased food intake, protein gain and energetic efficiency. In female animals, TPM reduced energetic efficiency while it stimulated lipoprotein lipase activity in brown adipose tissue. TPM also reduced plasma glucose and plasma leptin levels in female rats as well as plasma insulin and liver triglycerides in male animals. As expected, castration and sex hormones also strongly influenced energy balance. In male rats, OCX led to a decrease in energy and protein gains that was blocked by treatment with testosterone. In female rats, OVX caused increases in energy, fat and protein gains that were prevented by treatment with estradiol.
CONCLUSION: In female rats, the effects of TPM on fat and energy gains were clearly not influenced by the sex hormone status of the rats. In male animals, there was also no interaction of TPM and the status of sex hormones on energy balance, suggesting that OCX and testosterone minimally interfere with the action of TPM on energy balance. The effects of TPM on energy balance were accounted for by a decrease in energetic efficiency, resulting from an effect exerted by the drug on both energy intake and thermogenesis. The present results also suggest that TPM can enhance insulin sensitivity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11896489     DOI: 10.1038/sj.ijo.0801873

Source DB:  PubMed          Journal:  Int J Obes Relat Metab Disord


  17 in total

Review 1.  Hypothalamic regulatory pathways and potential obesity treatment targets.

Authors:  Erin E Jobst; Pablo J Enriori; Puspha Sinnayah; Michael A Cowley
Journal:  Endocrine       Date:  2006-02       Impact factor: 3.633

2.  The effect of topiramate on energy balance in obese men: a 6-month double-blind randomized placebo-controlled study with a 6-month open-label extension.

Authors:  Angelo Tremblay; Jean-Philippe Chaput; Sonia Bérubé-Parent; Denis Prud'homme; Claude Leblanc; Natalie Alméras; Jean-Pierre Després
Journal:  Eur J Clin Pharmacol       Date:  2007-01-03       Impact factor: 2.953

3.  Treating epilepsy in the setting of medical comorbidities.

Authors:  Nivedita U Jerath; Dronacharya Lamichhane; Madhu Jasti; Vinusha Yarlagadda; Eduardo Zilli; Yara Nazzal; Mark Granner
Journal:  Curr Treat Options Neurol       Date:  2014-07       Impact factor: 3.598

4.  Topiramate augments the antipsychotic-like effect and cortical dopamine output of raclopride.

Authors:  Amani Eltayb; Marie-Louise G Wadenberg; Björn Schilström; Torgny H Svensson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-11-12       Impact factor: 3.000

Review 5.  Opportunities and challenges in the therapeutic activation of human energy expenditure and thermogenesis to manage obesity.

Authors:  Kong Y Chen; Robert J Brychta; Zahraa Abdul Sater; Thomas M Cassimatis; Cheryl Cero; Laura A Fletcher; Nikita S Israni; James W Johnson; Hannah J Lea; Joyce D Linderman; Alana E O'Mara; Kenneth Y Zhu; Aaron M Cypess
Journal:  J Biol Chem       Date:  2019-12-30       Impact factor: 5.157

Review 6.  Role of antiepileptic drugs in the management of eating disorders.

Authors:  Susan L McElroy; Anna I Guerdjikova; Brian Martens; Paul E Keck; Harrison G Pope; James I Hudson
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

Review 7.  Psychotropic drugs in the treatment of obesity: what promise?

Authors:  Jose C Appolinario; João R Bueno; Walmir Coutinho
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 8.  Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate.

Authors:  Richard P Shank; Bruce E Maryanoff
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

Review 9.  Antiobesity pharmacotherapy: new drugs and emerging targets.

Authors:  G W Kim; J E Lin; E S Blomain; S A Waldman
Journal:  Clin Pharmacol Ther       Date:  2013-10-08       Impact factor: 6.875

Review 10.  Centrally Acting Agents for Obesity: Past, Present, and Future.

Authors:  Ann A Coulter; Candida J Rebello; Frank L Greenway
Journal:  Drugs       Date:  2018-07       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.